Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tirzepatide on Oral Contraceptive PK
NCT04172987Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol, Maximum Concentration (Cmax) of Ethinylestradiol and 2 more. Started Feb 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04172987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172987.